GENETIC, PATHOLOGICAL, BIOMARKERS, AND HEREDITARY FACTORS ASSOCIATED WITH PRE-ECLAMPSIA

B KANNAKI DEVI
Ph.D. Research Scholar
Department of Computer Science
Bharathiar University
Coimbatore, Tamil Nadu, India
kavipalanichamy@gmail.com

Dr D RAMYACHITRA
Associate Professor
Department of Computer Science
Bharathiar University
Coimbatore, Tamil Nadu, India
ramyachitra@buc.edu.in

***Abstract*— Pre-eclampsia remains a significant challenge in obstetrics, characterized by hypertension and proteinuria after 20 weeks of gestation, with potential severe complications for both mother and fetus. This review synthesizes current knowledge on the genetic, pathological, biomarker, and family history factors associated with pre-eclampsia. Genetic predisposition plays a crucial role, with studies identifying candidate genes involved in vascular function, immune response, and placental development. Pathologically, impaired placentation and maternal vascular maladaptation contribute to the condition, leading to systemic endothelial dysfunction and organ damage. Biomarkers such as PlGF, sFLT-1, and sENG have shown promise in early detection and risk stratification, though challenges remain in their clinical utility. Family history studies underscore a familial aggregation of risk, implicating shared genetic and environmental factors. Integrating these factors provides a comprehensive understanding of pre-eclampsia's complex etiology, highlighting avenues for improved prediction, management, and future research directions.**

Keywords — *Pre-eclampsia, Genetic predisposition, Pathological mechanisms, Biomarkers, Hereditary factors*

I. INTRODUCTION

Pre-eclampsia, a multisystem disorder unique to pregnancy, remains a significant cause of maternal and fetal morbidity and mortality worldwide. Characterized by hypertension and proteinuria after 20 weeks of gestation, pre-eclampsia affects approximately 2-8% of pregnancies globally, with variations depending on geographical and demographic factors (ACOG, 2019). Despite extensive research efforts, the precise etiology of pre-eclampsia remains incompletely understood, reflecting its complex interplay of genetic, pathological, biomarker, and hereditary factors.

This review aims to delve into the multifaceted nature of pre-eclampsia by examining the contributions of genetic predisposition, underlying pathological mechanisms, emerging biomarkers, and hereditary influences. Genetic factors play a pivotal role in predisposing individuals to pre-eclampsia, involving variations in genes regulating vascular function, immune response, and placental development (ACOG, 2020). Concurrently, pathological insights reveal compromised placental perfusion and maternal vascular maladaptation as central mechanisms contributing to endothelial dysfunction and systemic manifestations of the disorder (Roberts and Escudero, 2012).

Biomarkers, such as Placental Growth Factor (PlGF), soluble Fms-like tyrosine kinase-1 (sFLT-1), and soluble Endoglin (sENG), have emerged as promising tools for early detection, risk stratification, and monitoring of pre-eclampsia (Verlohren et al., 2012). Their utility in clinical practice, however, requires continued validation and refinement. Moreover, hereditary factors beyond genetic predisposition, including familial clustering and shared environmental influences, underscore the broader implications of familial history in understanding disease susceptibility.

By synthesizing current research findings across these domains, this review aims to provide a comprehensive overview of the intricate mechanisms underpinning pre-eclampsia. Understanding these factors not only enhances our grasp of the disorder's pathophysiology but also paves the way for improved diagnostic strategies, personalized management approaches, and avenues for future research.

Genetic predisposition plays a crucial role in the susceptibility to pre-eclampsia. Research has identified variations in genes involved in vascular function, immune response, and placental development as significant contributors to the pathogenesis of the disorder (ACOG, 2020). For instance, genes regulating endothelial function (e.g., ACE, AGT), immune modulation (e.g., HLA-G, TNF-α), and angiogenic factors (e.g., VEGF, PlGF) have been implicated in altering an individual's risk of developing pre-eclampsia (Vaiman et al., 2015). These genetic variations influence processes such as placental development and vascular adaptation during pregnancy,

thereby impacting maternal cardiovascular health and fetal outcomes.

Pathologically, pre-eclampsia is characterized by aberrant placental development and maternal vascular maladaptation. In normal pregnancies, the placenta undergoes extensive remodeling of the uteroplacental circulation to ensure optimal blood flow and nutrient exchange between the mother and fetus. In pre-eclampsia, this process is disrupted, leading to inadequate placental perfusion, ischemia-reperfusion injury, and oxidative stress (Roberts and Escudero, 2012). These pathological changes trigger the release of anti-angiogenic factors such as soluble Fms-like tyrosine kinase-1 (sFLT-1) and soluble Endoglin (sENG) into the maternal circulation, which contribute to endothelial dysfunction and systemic manifestations of the disorder.

Emerging biomarkers have shown promise in the early detection, risk stratification, and monitoring of pre-eclampsia. Placental Growth Factor (PlGF), for example, is a key angiogenic factor whose reduced levels have been associated with an increased risk of developing pre-eclampsia (Verlohren et al., 2012). The ratio of soluble Fms-like tyrosine kinase-1 (sFLT-1) to PlGF in maternal blood has emerged as a valuable biomarker for predicting the onset and severity of pre-eclampsia, offering clinicians a tool for early intervention and management (Zeisler et al., 2016).

In addition to genetic predisposition, hereditary factors such as familial clustering and shared environmental influences play significant roles in the susceptibility to pre-eclampsia. Epidemiological studies have consistently demonstrated an increased risk of pre-eclampsia among women with a maternal history of the condition, highlighting familial aggregation as a strong predictor of disease risk (Hernandez-Diaz et al., 2009).

II. RELATED WORKS

Vaiman et al., [1] This study explores transcriptional changes in the placenta of women with pre-eclampsia, aiming to identify genetic deregulations that may contribute to the development of the condition. By analyzing gene expression patterns, the researchers provide insights into potential genetic factors involved in pre-eclampsia pathogenesis.

Bellamy L et al., [2] This meta-analysis examines genetic and epidemiological evidence linking pre-eclampsia to increased risk of cardiovascular disease and cancer in later life. It explores genetic predisposition as a potential shared factor contributing to both conditions.

Van Dijk M et al., [3] This research identifies a specific genetic locus associated with familial clustering of pre-eclampsia in the Dutch population. The study implicates a novel member of the winged helix gene family in the genetic susceptibility to pre-eclampsia.

Roberts JM et al., [4] This paper presents the "two-stage model" of pre-eclampsia, which proposes that inadequate placental perfusion (first stage) leads to the release of factors into the maternal circulation (second stage), causing systemic endothelial dysfunction and clinical manifestations of pre-eclampsia. It discusses variations and updates to this model based on current research.

Soleymanlou N et al., [6] This study provides molecular evidence supporting the role of placental hypoxia in the pathogenesis of pre-eclampsia. It examines gene expression patterns indicative of hypoxic stress and their implications for maternal endothelial dysfunction and clinical outcomes.

Levine RJ et al., [7] This landmark study identifies angiogenic factors, including soluble Fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF), as biomarkers associated with the risk of developing pre-eclampsia. It establishes their potential utility for early prediction and diagnosis of the condition.

Verlohren S et al., [8] This study establishes new cutoff values for the soluble fms-like tyrosine kinase-1 (sFLT-1) to placental growth factor (PlGF) ratio, a biomarker used to predict and diagnose pre-eclampsia. By defining specific thresholds for different stages of pregnancy, the researchers aim to improve the accuracy of this biomarker in clinical practice.

Zeisler H et al., [9] This multicenter study evaluates the predictive value of the soluble fms-like tyrosine kinase-1 (sFLT-1) to placental growth factor (PlGF) ratio in women presenting with suspected pre-eclampsia. It assesses the biomarker's performance in differentiating between women who will develop pre-eclampsia and those who will not, aiding in clinical decision-making.

Esplin MS et al., [10] This study investigates both paternal and maternal contributions to the genetic predisposition for pre-eclampsia, providing insights into familial clustering and genetic risk factors transmitted through both parents.

Laivuori H et al., [11] This genetic linkage study identifies specific susceptibility loci on chromosomes 2p25 and 9p13 associated with familial clustering of pre-eclampsia in Finnish populations, highlighting potential regions of interest for further genetic research.

Brosens I et al., [13] This review article discusses the concept of the "Great Obstetrical Syndromes," including pre-eclampsia, and their association with impaired deep placentation. It explores the pathological mechanisms underlying placental dysfunction and maternal vascular maladaptation.

Redman CW et al., [14] This article summarizes recent advances in understanding the pathological mechanisms of pre-eclampsia, including immune maladaptation, oxidative stress, and placental dysfunction. It highlights key research findings that contribute to evolving theories of disease pathogenesis.

Skjaerven R et al., [19] This population-based cohort study investigates the recurrence of pre-eclampsia across generations, examining both fetal and maternal genetic contributions. The research highlights the hereditary nature of pre-eclampsia and explores potential genetic factors that may predispose individuals to the condition based on familial history.

III. GENETIC FACTORS ASSOCIATED WITH PRE-ECLAMPSIA

Pre-eclampsia is known to have a significant genetic component, influencing the predisposition to this complex pregnancy disorder. Genetic studies have identified various genes and genetic variations that contribute to the pathogenesis of pre-eclampsia, affecting processes such as vascular function, immune response, and placental development.

3.1 GENETIC PREDISPOSITION: OVERVIEW AND EVIDENCE

Genetic predisposition to pre-eclampsia is well-established, with familial clustering and heritability patterns indicating a strong genetic influence. Several genetic susceptibility loci and candidate genes have been implicated through linkage studies, genome-wide association studies (GWAS), and candidate gene approaches.

(i) FAMILIAL AGGREGATION

Studies have consistently shown that women with a family history of pre-eclampsia are at higher risk of developing the condition themselves (Skjaerven et al., 2005). This familial clustering suggests that genetic factors play a crucial role in disease susceptibility.

(ii) HERITABILITY ESTIMATES

Heritability studies have estimated that genetic factors contribute to approximately 30-60% of the variability in pre-eclampsia risk (Esplin et al., 2001). This indicates a substantial genetic component underlying the disorder.

3.2 KEY GENES AND PATHWAYS IMPLICATED IN PRE-ECLAMPSIA

Various genes involved in vascular function, immune modulation, and placental development have been identified as key players in pre-eclampsia pathogenesis.

(i) GENES REGULATING VASCULAR FUNCTION

Genes encoding proteins involved in vascular tone regulation, such as angiotensinogen (AGT) and angiotensin-converting enzyme (ACE), have been associated with altered vascular responses and hypertension observed in pre-eclampsia (ACOG, 2020).

(ii) IMMUNE RESPONSE GENES

Genetic variations in immune response genes, including human leukocyte antigen-G (HLA-G) and tumor necrosis factor-alpha (TNF-α), have been linked to abnormal immune tolerance and inflammatory responses implicated in pre-eclampsia (Vaiman et al., 2015).

(iii) PLACENTAL DEVELOPMENT GENES

Genes critical for placental development and function, such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), play crucial roles in ensuring adequate placental perfusion and fetal nutrient supply. Alterations in these genes have been associated with impaired placental development and pre-eclampsia pathophysiology (ACOG, 2020).

3.3. EPIGENETIC MECHANISMS AND THEIR ROLE IN DISEASE SUSCEPTIBILITY

Epigenetic modifications, which regulate gene expression without altering the underlying DNA sequence, have emerged as important contributors to pre-eclampsia susceptibility.

(i) *DNA METHYLATION:* Aberrant DNA

Methylation patterns in genes related to vascular function and placental development have been observed in pre-eclampsia cases (Roberts and Escudero, 2012). These epigenetic changes may influence gene expression patterns critical for normal pregnancy adaptation.

(ii) *HISTONE MODIFICATIONS*

Alterations in histone modifications, such as acetylation and methylation, can impact chromatin structure and gene accessibility, affecting pathways involved in vascular homeostasis and immune regulation (Roberts and Escudero, 2012).

(iii) *MICRORNAS (MIRNAS)*

Dysregulated expression of miRNAs, small non-coding RNAs that post-transcriptionally regulate gene expression,

has been implicated in pre-eclampsia pathogenesis (ACOG, 2020). These miRNAs can target genes involved in angiogenesis, inflammation, and placental function, contributing to disease manifestations.

IV. PATHOLOGICAL FACTORS UNDERLYING PRE-ECLAMPSIA

Pre-eclampsia, a serious pregnancy complication, is driven by several key pathological factors. The condition is characterized by inadequate placental development and poor blood flow, which lead to reduced oxygen and nutrient supply to the fetus and trigger stress responses in the placenta (Redman and Sargent, 2005). This placental dysfunction contributes to endothelial dysfunction, where blood vessel linings fail to function properly, causing hypertension and proteinuria in mothers (Redman and Sargent, 2005). Additionally, oxidative stress amplifies inflammation and damages blood vessels, exacerbating pre-eclampsia symptoms (Burton et al., 2009). The immune system's heightened response further complicates matters, promoting inflammation that worsens vascular damage and disrupts placental function (Staff et al., 2010). Increased levels of anti-angiogenic factors, such as sFLT-1 and sENG, interfere with normal blood vessel growth and exacerbate hypertension and kidney issues in affected mothers (Maynard et al., 2003). Genetic variations and epigenetic changes also play roles in altering placental and immune functions, influencing the onset and severity of pre-eclampsia (Roberts and Escudero, 2012). Understanding these complex pathological mechanisms is crucial for developing effective treatments and preventive strategies to improve outcomes for both mothers and babies affected by pre-eclampsia.Key pathological factors implicated in the development of pre-eclampsia

4.1 PLACENTAL DYSFUNCTION AND INSUFFICIENT TROPHOBLAST INVASION

Pre-eclampsia is often associated with abnormal placentation, characterized by inadequate invasion of trophoblast cells into the maternal spiral arteries. This results in incomplete remodeling of uteroplacental circulation, leading to reduced placental perfusion and oxygenation.

4.2 ENDOTHELIAL DYSFUNCTION

The hallmark of pre-eclampsia is systemic endothelial dysfunction, characterized by impaired vasodilation, increased vascular permeability, and activation of coagulation pathways.

4.3 OXIDATIVE STRESS AND IMBALANCE OF ANTI-OXIDANTSYSTEMS:

Placental ischemia-reperfusion injury generates reactive oxygen species (ROS) and reduces antioxidant defenses, resulting in oxidative stress.

4.4 GENETIC AND EPIGENETIC FACTORS

Genetic variations and epigenetic modifications influence susceptibility to pre-eclampsia, affecting pathways related to placental development, immune function, and vascular regulation.

V. BIOMARKERSAFFECTING PRE-ECLAMPSIA

Biomarkers play a crucial role in the detection, prediction, and management of pre-eclampsia, offering insights into its pathophysiology and aiding clinical decision-making. Several biomarkers have been identified that are associated with pre-eclampsia:

5.1 PLACENTAL GROWTH FACTOR (PLGF)

PlGF is a vascular endothelial growth factor involved in angiogenesis and placental development. In pre-eclampsia, PlGF levels are reduced due to impaired placental function and increased production of anti-angiogenic factors like sFLT-1, contributing to endothelial dysfunction and hypertension (Levine et al., 2004).

5.2 SOLUBLE FMS-LIKE TYROSINE KINASE-1 (SFLT-1)

sFLT-1 is a soluble receptor for VEGF and PlGF, acting as an anti-angiogenic factor by binding and inhibiting these growth factors. Elevated levels of sFLT-1 in pre-eclampsia contribute to endothelial dysfunction, hypertension, and proteinuria (Maynard et al., 2003).

5.3 SOLUBLE ENDOGLIN (SENG)

sENG is another anti-angiogenic protein elevated in pre-eclampsia, which binds to TGF-β receptors and interferes with normal vascular endothelial function. Increased sENG levels are associated with impaired placental perfusion and endothelial dysfunction (Venkatesha et al., 2006).

5.4 PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A)

PAPP-A is a protease that regulates insulin-like growth factor bioavailability. Low levels of PAPP-A early in pregnancy are associated with increased risk of developing pre-eclampsia, reflecting impaired placentation and fetal growth (Conover, 2012).

5.5 CIRCULATING MICRORNAS (MIRNAS)

miRNAs are small non-coding RNAs that regulate gene expression. Dysregulated miRNAs in pre-eclampsia have been identified in maternal circulation and placental tissues, reflecting altered pathways involved in angiogenesis, inflammation, and vascular function (Zhao et al., 2013).

5.6 OTHER BIOMARKERS

Additional biomarkers under investigation include markers of oxidative stress (e.g., malondialdehyde), inflammatory cytokines (e.g., TNF-α, IL-6), and markers of endothelial dysfunction (e.g., von Willebrand factor). These biomarkers provide insights into specific aspects of pre-eclampsia pathophysiology and may offer potential targets for therapeutic interventions and personalized management strategies (ACOG, 2020).

VI. HEREDITARY FACTORS AFFECTING PRE-ECLAMPSIA

Hereditary factors play a significant role in the predisposition to pre-eclampsia, influencing both genetic susceptibility and familial clustering of the condition. Here are key hereditary factors associated with pre-eclampsia:

6.1 FAMILY HISTORY

Pre-eclampsia tends to run in families, suggesting a genetic predisposition. Women with a first-degree relative (mother or sister) who had pre-eclampsia are at higher risk themselves, indicating familial clustering (Skjaerven et al., 2005).

6.2 GENETIC VARIATIONS

Several genes have been implicated in pre-eclampsia susceptibility, primarily those involved in vascular function, immune response, and placental development. Variations in genes encoding proteins such as angiotensinogen (AGT), nitric oxide synthase (NOS), and cytokines like TNF-α have been associated with altered maternal vascular responses and immune modulation during pregnancy (ACOG, 2020).

6.3 HYPERTENSION AND CARDIOVASCULAR DISEASE RISK GENES

Genetic variants associated with hypertension and cardiovascular diseases (CVD) have also been linked to increased risk of pre-eclampsia. These include genes involved in regulating blood pressure, vascular tone, and endothelial function, such as ACE (angiotensin-converting enzyme) and genes related to lipid metabolism (Roberts and Escudero, 2012).

6.4 EPIGENETIC MODIFICATIONS

Epigenetic changes, which alter gene expression without affecting the DNA sequence, can influence susceptibility to pre-eclampsia. These modifications, including DNA methylation and histone modifications, regulate placental development, immune responses, and vascular function during pregnancy (ACOG, 2020).

6.5 MATERNAL AND ENVIRONMENTAL INTERACTIONS

Maternal factors, such as age, body mass index (BMI), and underlying health conditions (e.g., diabetes, renal disease), interact with genetic predispositions to influence pre-eclampsia risk. Environmental factors, including diet, stress, and exposure to pollutants, also contribute to the complex interplay of hereditary and environmental influences (ACOG, 2020).

VII. CONCLUSIONS

In conclusion, pre-eclampsia remains a complex and multifactorial pregnancy disorder influenced by a combination of genetic predisposition, pathological mechanisms, biomarkers, and hereditary factors. Genetic studies have identified various genes involved in vascular function, immune response, and placental development that contribute to susceptibility. Pathologically, inadequate placental perfusion, endothelial dysfunction, oxidative stress, and an exaggerated inflammatory response play critical roles in the development of pre-eclampsia. Biomarkers like PlGF, sFLT-1, and sENG have shown promise in early detection and monitoring, though their clinical utility requires further validation. Additionally, familial clustering and genetic variations underscore the hereditary nature of pre-eclampsia, emphasizing the importance of personalized risk assessment and management strategies. Moving forward, continued research into these factors is essential for improving our understanding, early diagnosis, and ultimately, the prevention and treatment of pre-eclampsia to mitigate its significant maternal and fetal health impacts.

References

[1] Vaiman D, Calicchio R, Miralles F. Landscape of transcriptional deregulations in the preeclamptic placenta. PLoS One. 2013 Jun 13;8(6):e65498. doi: 10.1371/journal.pone.0065498. PMID: 23785430; PMCID: PMC3681798.

[2] Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 Nov 10;335(7627):974. doi: 10.1136/bmj.39335.385301.BE. Epub 2007 Nov 1. PMID: 17975258; PMCID: PMC2072042.

[3] van Dijk M, Mulders J, Poutsma A, Könst AA, Lachmeijer AM, Dekker GA, Blankenstein MA, Oudejans CB. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet. 2005 May;37(5):514-9. doi: 10.1038/ng1541. Epub 2005 Apr 3. PMID: 15806103.

[4] Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009 Mar;30 Suppl A(Suppl A):S32-7. doi: 10.1016/j.placenta.2008.11.009. Epub 2008 Dec 13. PMID: 19070896; PMCID: PMC2680383.

[5] Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005 Jun 10;308(5728):1592-4. doi: 10.1126/science.1111726. PMID: 15947178.

[6] Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005 Jul;90(7):4299-308. doi: 10.1210/jc.2005-0078. Epub 2005 Apr 19. PMID: 15840747; PMCID: PMC6428057.

[7] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. doi: 10.1056/NEJMoa031884. Epub 2004 Feb 5. PMID: 14764923.

[8] Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014 Feb;63(2):346-52. doi: 10.1161/HYPERTENSIONAHA.113.01787. Epub 2013 Oct 28. PMID: 24166751.

[9] Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016 Jan 7;374(1):13-22. doi: 10.1056/NEJMoa1414838. PMID: 26735990.

[10] Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001 Mar 22;344(12):867-72. doi: 10.1056/NEJM200103223441201. PMID: 11259719.

[11] Laivuori H, Lahermo P, Ollikainen V, Widen E, Häivä-Mällinen L, Sundström H, Laitinen T, Kaaja R, Ylikorkala O, Kere J. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet. 2003 Jan;72(1):168-77. doi: 10.1086/345311. Epub 2002 Dec 9. PMID: 12474145; PMCID: PMC378622.

[12] ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. doi: 10.1097/AOG.0000000000003018. PMID: 30575675.

[13] Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011 Mar;204(3):193-201. doi: 10.1016/j.ajog.2010.08.009. Epub 2010 Nov 20. PMID: 21094932; PMCID: PMC3369813.

[14] Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010 Jun;63(6):534-43. doi: 10.1111/j.1600-0897.2010.00831.x.Epub 2010 Mar 23. PMID: 20331588.

[15] Dimitriadis, E., Rolnik, D.L., Zhou, W. et al. Pre-eclampsia. Nat Rev Dis Primers 9, 8 (2023). https://doi.org/10.1038/s41572-023-00417-6

[16] Tarca AL, Romero R, Benshalom-Tirosh N, Than NG, Gudicha DW, Done B, Pacora P, Chaiworapongsa T, Panaitescu B, Tirosh D, Gomez-Lopez N, Draghici S, Hassan SS, Erez O. The prediction of early preeclampsia: Results from a longitudinal proteomics study. PLoS One. 2019 Jun 4;14(6):e0217273. doi: 10.1371/journal.pone.0217273. PMID: 31163045; PMCID: PMC6548389.

[17] Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005 Jan;17(1):3-18. doi: 10.1080/14767050400028816. PMID: 15804781.

[18] Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21;125(7):911-9. doi: 10.1161/CIRCULATIONAHA.111.054361. Epub 2012 Jan 18. PMID: 22261192; PMCID: PMC3319742.

[19] Skjaerven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005 Oct 15;331(7521):877. doi: 10.1136/bmj.38555.462685.8F. Epub 2005 Sep 16. PMID: 16169871; PMCID: PMC1255793.

[20] GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet. 2005 Jul;77(1):127-31. doi: 10.1086/431245. Epub 2005 May 11. PMID: 15889386; PMCID: PMC1226184.

[21] Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin ObstetGynaecol. 2011 Aug;25(4):405-17. doi: 10.1016/j.bpobgyn.2011.02.007. Epub 2011 Mar 22. PMID: 21429808; PMCID: PMC3145161.